Dopaminergic function and progression of Parkinson's disease: PET findings
- PMID: 20123555
- DOI: 10.1016/S1353-8020(09)70833-8
Dopaminergic function and progression of Parkinson's disease: PET findings
Abstract
Recent PET studies in Parkinson's disease (PD) have shown that the progression of neurodegeneration follows an exponential decay pattern. Most of the damage to the nigrostriatal dopamine system occurs during the presymptomatic phase of the disease and the first few years following symptom onset. The progressive loss of dopaminergic neurons is accompanied by several functional adaptive changes in surviving nerve terminals, which lead to increased dopamine turnover and raise the risk of treatment-related motor complications. Younger PD patients seem to have more efficient compensatory mechanisms and a slower rate of progression of neurodegeneration.
Copyright 2009 Elsevier Ltd. All rights reserved.
Similar articles
-
Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.Prog Brain Res. 2010;184:177-92. doi: 10.1016/S0079-6123(10)84009-9. Prog Brain Res. 2010. PMID: 20887875 Review.
-
PET studies of the striatal dopaminergic system in Parkinson's disease (PD).J Neural Transm Suppl. 1995;45:123-31. J Neural Transm Suppl. 1995. PMID: 8748617 Review.
-
Age-specific progression of nigrostriatal dysfunction in Parkinson's disease.Ann Neurol. 2011 May;69(5):803-10. doi: 10.1002/ana.22284. Epub 2011 Jan 18. Ann Neurol. 2011. PMID: 21246604
-
Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.J Neurol Sci. 2011 Nov 15;310(1-2):40-3. doi: 10.1016/j.jns.2011.07.029. Epub 2011 Aug 15. J Neurol Sci. 2011. PMID: 21840542 Review.
-
Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.Neuroimage Clin. 2017 Mar 27;14:734-740. doi: 10.1016/j.nicl.2017.03.011. eCollection 2017. Neuroimage Clin. 2017. PMID: 28409113 Free PMC article.
Cited by
-
The sensitivity and specificity of F-DOPA PET in a movement disorder clinic.Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):102-9. eCollection 2016. Am J Nucl Med Mol Imaging. 2016. PMID: 27069770 Free PMC article.
-
Paraquat and psychological stressor interactions as pertains to Parkinsonian co-morbidity.Neurobiol Stress. 2015 Nov 12;2:85-93. doi: 10.1016/j.ynstr.2015.09.001. eCollection 2015. Neurobiol Stress. 2015. PMID: 26844243 Free PMC article.
-
The diagnostic value of minor salivary gland biopsy in clinically diagnosed patients with Parkinson's disease: comparison with DAT PET scans.Neurol Sci. 2015 Sep;36(9):1575-80. doi: 10.1007/s10072-015-2190-5. Epub 2015 Mar 28. Neurol Sci. 2015. PMID: 25820147
-
How to design PET experiments to study neurochemistry: application to alcoholism.Yale J Biol Med. 2014 Mar 5;87(1):33-54. eCollection 2014 Mar. Yale J Biol Med. 2014. PMID: 24600335 Free PMC article. Review.
-
CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.J Neural Transm (Vienna). 2012 Jul;119(7):861-75. doi: 10.1007/s00702-012-0820-0. Epub 2012 May 24. J Neural Transm (Vienna). 2012. PMID: 22622365 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical